News
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
The pharmaceutical firm Novo Nordisk is pursuing a multipronged strategy to regain market share that it has lost to Eli Lilly ...
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...
Novo Nordisk ( NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m. ET, it was ...
The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...
Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...
Hims & Hers Health, Inc. teams up with Novo Nordisk to offer Wegovy at $599/month, slashing costs. Click for why this is a ...
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...
Hims and Hers Health Inc. soared in pre-market trading after Novo Nordisk A/S said it would sell its popular weight-loss drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results